Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial
- Authors
- Ahn, Jong Hyeon; Kim, Minkyeong; Park, Suyeon; Jang, Wooyoung; Park, Jinse; Oh, Eungseok; Cho, Jin Whan; Kim, Ji Sun; Youn, Jinyoung
- Issue Date
- Jun-2020
- Publisher
- Elsevier BV
- Keywords
- Sleep disturbance; Parkinson's disease; Melatonin; Circadian rhythm; Prolonged-release melatonin
- Citation
- Parkinsonism and Related Disorders, v.75, pp 50 - 54
- Pages
- 5
- Journal Title
- Parkinsonism and Related Disorders
- Volume
- 75
- Start Page
- 50
- End Page
- 54
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19501
- DOI
- 10.1016/j.parkreldis.2020.03.029
- ISSN
- 1353-8020
1873-5126
- Abstract
- Background: The present study was a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the efficacy and safety of prolonged-release melatonin (PRM) in Parkinson's disease (PD) patients with poor sleep quality. Methods: PD patients with a global Pittsburgh Sleep Quality Index (PSQI) score > 5 were included. Patients were assessed using the PSQI, a rapid eye movement sleep behavior disorder screening questionnaire, the Epworth Sleepiness Scale, Non-Motor Symptoms Scale (NMSS), Parkinson's Disease Quality of Life-39 (PDQ-39), and Unified Parkinson's Disease Rating Scale (UPDRS)-III at the beginning of the study and after 4 weeks of treatment with 2 mg of PRM. Partial correlation analysis was performed to investigate the relationship between PSQI score and the other scales. Results: Thirty-four PD patients with poor sleep quality were enrolled and divided into 2 groups based on medication; PRM (n = 16) and placebo (n = 18). Regarding efficacy, PSQI was significantly improved in the PRM group compared to the control group. Improvement in the NMSS and PDQ-39 summary index were observed in the PRM but not in the placebo group; UPDRS-III score was not significantly changed in either group. PSQI improvement correlated with improvement in NMSS score and PDQ-39 summary index. Regarding safety, all enrolled subjects did not complain of side effects due to PRM. Conclusion: PRM is an effective and safe treatment option for subjective sleep quality in PD patients and beneficial effects on sleep quality are associated with improved non-motor symptoms and quality of life in PD patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19501)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.